{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:18:30Z","timestamp":1781533110463,"version":"3.54.5"},"reference-count":17,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Immunophenotypic variations in mantle cell lymphoma (MCL) from the classic CD5+\/CD10\u2212\/CD23\u2212\/FMC-7+ immunophenotype have been reported in the literature, but correlation with clinical behavior and outcome has not been fully studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To investigate clinicopathologic and prognostic differences between immunophenotypically aberrant MCL and immunophenotypically typical MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We evaluated differences in clinical presentation, laboratory parameters, prognostic indices, response to initial treatment, and progression-free and overall survival between patients with aberrant MCL and patients with immunophenotypically typical MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>There were 158 patients with newly diagnosed cyclin D1 or t(11;14)(q13;q32)+ MCL identified in the original search, of which, 29 patients (18%) showed immunophenotypic aberrancies, with CD23 coexpression being the most common. When compared with 33 randomly selected patients with immunophenotypically typical MCL, statistically significant differences were seen in white blood cell counts (P = .02), in the presence of absolute lymphocytosis (P = .03), in the MCL International Prognostic Index score (P = .02), and in response to initial treatment (P = .04). The \u201cimmunophenotypic status\u201d of the MCL was the only independent factor associated with response to treatment (P = .05), but not with the MCL International Prognostic Index score, absolute lymphocytosis, or white blood cell count. No significant differences were seen for progression-free or overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Immunophenotypic variations in MCL are associated with differences in clinical presentation and response to therapy when compared with immunophenotypically typical MCL. However, with current intensive frontline immunochemotherapy, immunophenotypic aberrations do not appear to affect progression-free or overall survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2017-0368-oa","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T09:33:07Z","timestamp":1528191187000},"page":"1268-1274","source":"Crossref","is-referenced-by-count":7,"title":["Immunophenotypic Variations in Mantle Cell Lymphoma and Their Impact on Clinical Behavior and Outcome"],"prefix":"10.5858","volume":"142","author":[{"given":"Barina","family":"Aqil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Triska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Frater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjum","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna B.","family":"Ruzinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cashen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Kreisel","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Immunology (Drs Aqil, Frater, Hassan, Ruzinova, and Kreisel), and Internal Medicine (Ms Triska and Dr Cashen), Washington University School of Medicine, St Louis, Missouri; and the Clinical Laboratories, Barnes-Jewish Hospital, St Louis (Ms Reese)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"2020081300170915800_i1543-2165-142-10-1268-b01","first-page":"229","article-title":"Mantle cell lymphoma","author":"Swerdlow","year":"2008","journal-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4th ed"},{"issue":"2","key":"2020081300170915800_i1543-2165-142-10-1268-b02","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1309\/R94MAFJY5EA4A8C3","article-title":"CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23\u2212 disease","volume":"130","author":"Kelemen","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2020081300170915800_i1543-2165-142-10-1268-b03","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1309\/UQ4N-M5KL-0ANY-YD3G","article-title":"Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"116","author":"Gong","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2020081300170915800_i1543-2165-142-10-1268-b04","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1309\/XV4AG7EMWQU7ER67","article-title":"CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases","volume":"120","author":"Schlette","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2020081300170915800_i1543-2165-142-10-1268-b05","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic variations in mantle cell lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"2020081300170915800_i1543-2165-142-10-1268-b06","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jclinpath-2015-202955","article-title":"CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype?: insight, through gene expression profile in a unique case series","volume":"68","author":"Akhter","year":"2015","journal-title":"J Clin Pathol"},{"issue":"1","key":"2020081300170915800_i1543-2165-142-10-1268-b07","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2559.2008.03060.x","article-title":"Mantle cell lymphoma with aberrant expression of CD10","volume":"53","author":"Zanetto","year":"2008","journal-title":"Histopathology"},{"issue":"2","key":"2020081300170915800_i1543-2165-142-10-1268-b08","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1309\/U98ADVKUC26R2RJA","article-title":"B-cell lymphomas with coexpression of CD5 and CD10","volume":"119","author":"Dong","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2020081300170915800_i1543-2165-142-10-1268-b09","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1309\/TE56-A43X-29TT-5H8G","article-title":"CD5\u2212 mantle cell lymphoma","volume":"118","author":"Liu","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2020081300170915800_i1543-2165-142-10-1268-b10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"2020081300170915800_i1543-2165-142-10-1268-b11","first-page":"5761","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2020081300170915800_i1543-2165-142-10-1268-b12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.3880448","article-title":"Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases","volume":"14","author":"Schlette","year":"2001","journal-title":"Mod Pathol"},{"issue":"2","key":"2020081300170915800_i1543-2165-142-10-1268-b13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1309\/VWTK-XYT5-D0DK-06HQ","article-title":"Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification","volume":"115","author":"Garcia","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"2020081300170915800_i1543-2165-142-10-1268-b14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"2020081300170915800_i1543-2165-142-10-1268-b15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B","article-title":"Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group","volume":"64","author":"Weisenburger","year":"2000","journal-title":"Am J Hematol"},{"issue":"7","key":"2020081300170915800_i1543-2165-142-10-1268-b16","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1\u2013positive MCL and cyclin D1\u2013negative MCL-like B-cell lymphoma","volume":"95","author":"Yatabe","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2020081300170915800_i1543-2165-142-10-1268-b17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5858\/2008-132-1346-AUCOMC","article-title":"A unique case of mantle cell lymphoma with an aberrant CD5-\/CD10+ immunophenotype and typical morphology","volume":"132","author":"Sriganeshan","year":"2008","journal-title":"Arch Pathol Lab Med"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/10\/1268\/1447937\/arpa_2017-0368-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/10\/1268\/1447937\/arpa_2017-0368-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:33:54Z","timestamp":1764790434000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/142\/10\/article-p1268.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,6,5]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2017-0368-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]}}}